Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford, the Francis Crick Institute and University College London have been granted £1.7 million of funding from Cancer Research UK and the CRIS Cancer Foundation to develop a lung cancer vaccine.

Illustration in blue colors of a transparent human body with lungs with cancer cells in red © Shutterstock/ Sebastian Kaulitzki

Developed by scientists from the University of Oxford, the Francis Crick Institute and University College London, the ‘LungVax’ vaccine uses technology similar to the highly successful Oxford/AstraZeneca COVID-19 vaccine.

The team will receive funding for the study over the next 2 years to support lab research and initial manufacturing of 3,000 doses of the vaccine at the Oxford Clinical BioManufacturing Facility.

Lung cancer cells look different from normal cells due to having “red flag” proteins called neoantigens. Neoantigens appear on the surface of the cell because of cancer-causing mutations within the cell’s DNA.

The LungVax vaccine will carry a strand of DNA which trains the immune system to recognise these neoantigens on abnormal lung cells. The LungVax vaccine will then activate the immune system to kill these cells and stop lung cancer.


Read the full story on the University of Oxford website.